echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Northeast Pharmaceutical Carboprost Tromethamine Injection was awarded the "Drug Registration Certificate"

    Northeast Pharmaceutical Carboprost Tromethamine Injection was awarded the "Drug Registration Certificate"

    • Last Update: 2022-03-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On the evening of February 17, Northeast Pharmaceuticals announced that its wholly-owned subsidiary, No.


    Carboprost Tromethamine Injection (Carboprost Tromethamine Injection) was developed by Pfizer and was the first to market, with the trade name HEMABATE (Xin Mu Pei), mainly suitable for miscarriage at 13 weeks and 20 weeks of pregnancy and ineffective conventional treatment methods Postpartum hemorrhage caused by uterine atony


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.